
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics is a clinical-stage biotechnology and medical device development company that has a strong proprietary platform technology called PermaFusion, which enhances drug performance. With their ongoing clinical study for their lead program GX-03 in moderate-to-severe eczema showing potential and a favorable real-world tolerability record, the company has secured a path to advance its program without solely relying on immediate common equity raises. Additionally, their newly announced loan agreement with Avenue Venture for up to $25M, combined with their rapidly advancing pipeline, positions the company for potential growth and success in the near future.
Bears say
Turn Therapeutics is a clinical-stage biotechnology and medical device development company that is highly dependent on the success of its proprietary platform technology, PermaFusion. Unfortunately, the company has faced numerous challenges in recent clinical studies, leading to a delay in potential market approval. Additionally, the company's potential market, patients with moderate-to-severe eczema, is limited compared to other chronic inflammatory diseases, making it difficult for Turn to achieve significant revenue growth.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares